Optimizing Tumour Models to Empower Target Validation for IO Therapies

9:30 am - Tuesday 5th May 2026

  • Identifying and validating target orthologs in mice to ensure accurate immuneoncology efficacy studies
  • Employing syngeneic and xenograft mouse models and organoid systems to study tumour growth and immune response dynamics
  • Linking the data from these models to elucidate the mode of action of vaccines and guide translational strategies

Speakers:

Founder & Chief Scientific Officer
Hervolution Therapeutics